Packages (Simulation)
Reagent Preparation
Image (I)
Image (II)
Certificate
ELISA Kit for Fibrinogen Like Protein 1 (FGL1)
FGL-1; HFREP1; HP-041; LFIRE1; Hepassocin; Hepatocyte-derived fibrinogen-related protein 1; Liver fibrinogen-related protein 1
- Product No.SED022Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample Typeplasma
- Test MethodDouble-antibody Sandwich
- Assay Length3h
- Detection Range12.5-800ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 4.4ng/mL.
- DownloadInstruction Manual
- UOM 48T96T 96T*5 96T*10 96T*100
- FOB
US$ 490
For more details, please contact local distributors! US$ 700 US$ 3150 US$ 5950 US$ 49000
Specificity
This assay has high sensitivity and excellent specificity for detection of Fibrinogen Like Protein 1 (FGL1).
No significant cross-reactivity or interference between Fibrinogen Like Protein 1 (FGL1) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Fibrinogen Like Protein 1 (FGL1) and the recovery rates were calculated by comparing the measured value to the expected amount of Fibrinogen Like Protein 1 (FGL1) in samples.
Matrix | Recovery range (%) | Average(%) |
sodium citrate plasma(n=5) | 83-101 | 93 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Fibrinogen Like Protein 1 (FGL1) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Fibrinogen Like Protein 1 (FGL1) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Fibrinogen Like Protein 1 (FGL1) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
sodium citrate plasma(n=5) | 99-105% | 97-105% | 96-105% | 96-103% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
Standard | 2 | Standard Diluent | 1×20mL |
Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
Detection Reagent B | 1×120µL | Assay Diluent B | 1×12mL |
TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.
GIVEAWAYS
INCREMENT SERVICES
- Single-component Reagents of Assay Kit
- Lysis Buffer Specific for ELISA / CLIA
- Quality Control of Kit
- ELISA Kit Customized Service
- Disease Model Customized Service
- Serums Customized Service
- TGFB1 Activation Reagent
- Real Time PCR Experimental Service
- Streptavidin
- Fast blue Protein Stain solution
- Single-component Reagents of FLIA Kit
- Streptavidin-Agarose Beads
Magazine | Citations |
J Hepatol. | The role of Hepassocin in the development of non-alcoholic fatty liver disease Pubmed: 23792031 |
Diabetes Management | Serum hepassocin concentrations in diabetic patients with or without nonalcoholic fatty liver disease Futuremedicine:Source |
United States Patent Application | Compositions and Methods for Diagnosing Lung Cancer y2016:0077095.html |
Cell | Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC Doi: 10.1016/j.cell.2018.09.053 |
Liver Research | Do different bariatric surgery procedures impact hepassocin plasma levels in patients with type 2 diabetes mellitus? |
Impacts of Different Modes of Bariatric Surgery on Plasma Levels of Hepassocin in Patients with Diabetes Mellitus |